{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:48:49Z","timestamp":1777085329465,"version":"3.51.4"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Combination immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) leads to high response rates and improved survival in patients with advanced cutaneous melanoma (CM). Less is known about the efficacy of this combination in acral lentiginous melanoma (ALM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine the efficacy of combination immune checkpoint blockade targeting PD-1 and CTLA-4 in a diverse, real-world population of patients with ALM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multi-institutional retrospective study analysed patients with histologically confirmed ALM treated with a combination of PD-1 and CTLA-4 inhibitors between 2010 and 2022. The primary objective of the study was the objective response rate (ORR) as per the RECIST criteria. The secondary objectives were progression-free survival (PFS) and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 109 patients with advanced ALM treated with combined PD-1 and CTLA-4 blockade in any line of treatment were included. The majority of patients had stage IV disease (n = 81; 74.3%). The ORR for the entire cohort was 18.3% [95% confidence interval (CI) 11.6\u201326.9], with 9 (8.3%) complete and 11 (10.1%) partial responses. A further 22 patients (20.2%) had stable disease, and the disease control rate was 38.5%. Median PFS was 4.2\u2005months (95% CI 3.25\u20135.62), while median OS was 17\u2005months (95% CI 12.4\u201323.1). Ninety-five patients (87.2%) had a treatment-related adverse event, with 40.4% (n = 44\/109) experiencing at least one grade 3 or 4 toxicity. Elevated lactate dehydrogenase (P = 0.04), \u2265 2 lines of prior treatment (P = 0.03) and Asian ethnicity (P = 0.04) were associated with worse OS, while Hispanic\/Latino ethnicity was associated with better OS (P = 0.02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Combination PD-1 and CTLA-4 blockade is less effective for ALM than for CM, despite similar toxicity. In particular, Asian patients appear to derive less benefit from this regimen. Novel treatment approaches are needed for this rare melanoma subtype.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae401","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:52:00Z","timestamp":1729644720000},"page":"316-326","source":"Crossref","is-referenced-by-count":7,"title":["Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1293-8827","authenticated-orcid":false,"given":"Erin","family":"McGillivray","sequence":"first","affiliation":[{"name":"Department of Medicine, USC Keck School of Medicine , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karam","family":"Ashouri","sequence":"additional","affiliation":[{"name":"Department of Medicine, USC Keck School of Medicine , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7843-7160","authenticated-orcid":false,"given":"Eftychia","family":"Chatziioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Antonio Ocejo","family":"Gallegos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jabra","family":"Zarka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Kechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8769-2916","authenticated-orcid":false,"given":"Angelina S","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton","family":"Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew B","family":"Crocker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-4773","authenticated-orcid":false,"given":"Takuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo J","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarneem","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin B","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayant","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius de Lima","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonel F","family":"Hernandez Aya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Lutzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yana G","family":"Najjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collin\u00a0M","family":"Costello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron R","family":"Mangold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailender","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey T","family":"Gibney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M","family":"Farma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory\u00a0A","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Sosman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunandana","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Mangla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Bollin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia Abr\u00e3o","family":"Possik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Daniela","family":"Robles-Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumito","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gino K","family":"In","sequence":"additional","affiliation":[{"name":"Department of Medicine, USC Keck School of Medicine , Los Angeles, CA ,","place":["USA"]},{"name":"Division of Oncology, USC Keck School of Medicine, USC Norris Cancer Hospital , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"2025012411212467900_ljae401-B1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"2025012411212467900_ljae401-B2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"2025012411212467900_ljae401-B3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cell.2020.08.006","article-title":"Distinct classes of complex structural variation uncovered across thousands of cancer genome graphs","volume":"183","author":"Hadi","year":"2020","journal-title":"Cell"},{"key":"2025012411212467900_ljae401-B4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986\u20132005","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol"},{"key":"2025012411212467900_ljae401-B5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s12885-016-2747-6","article-title":"Racial differences in six major subtypes of melanoma: descriptive epidemiology","volume":"16","author":"Wang","year":"2016","journal-title":"BMC Cancer"},{"key":"2025012411212467900_ljae401-B6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"2025012411212467900_ljae401-B7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"2025012411212467900_ljae401-B8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025012411212467900_ljae401-B9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"2025012411212467900_ljae401-B10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/cas.13226","article-title":"Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma","volume":"108","author":"Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"key":"2025012411212467900_ljae401-B11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2019.08.014","article-title":"Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)","volume":"121","author":"Schadendorf","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025012411212467900_ljae401-B12","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025012411212467900_ljae401-B13","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/1346-8138.15804","article-title":"Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma","volume":"48","author":"Uhara","year":"2021","journal-title":"J Dermatol"},{"key":"2025012411212467900_ljae401-B14","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1634\/theoncologist.2014-0468","article-title":"Clinical activity of ipilimumab in acral melanoma: a retrospective review","volume":"20","author":"Johnson","year":"2015","journal-title":"Oncologist"},{"key":"2025012411212467900_ljae401-B15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/CMR.0000000000000465","article-title":"Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis","volume":"28","author":"H\u00e4fliger","year":"2018","journal-title":"Melanoma Res"},{"key":"2025012411212467900_ljae401-B16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2018.09.025","article-title":"Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: an open-label, single-arm, multicentre phase II study","volume":"105","author":"Namikawa","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025012411212467900_ljae401-B17","doi-asserted-by":"crossref","first-page":"e004668","DOI":"10.1136\/jitc-2022-004668","article-title":"Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma","volume":"10","author":"Bhave","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025012411212467900_ljae401-B18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2022.08.030","article-title":"Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: a retrospective, multicenter study of 254 Japanese patients","volume":"176","author":"Nakamura","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025012411212467900_ljae401-B19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00262-017-1989-8","article-title":"The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series","volume":"66","author":"Wen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"2025012411212467900_ljae401-B20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.02.026","article-title":"Response to immune checkpoint inhibitors in acral melanoma: a nationwide cohort study","volume":"167","author":"van Not","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025012411212467900_ljae401-B21","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/1346-8138.15521","article-title":"Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma","volume":"47","author":"Takahashi","year":"2020","journal-title":"J Dermatol"},{"key":"2025012411212467900_ljae401-B22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/1346-8138.16669","article-title":"Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma","volume":"50","author":"Takahashi","year":"2023","journal-title":"J Dermatol"},{"key":"2025012411212467900_ljae401-B23","doi-asserted-by":"crossref","first-page":"1229937","DOI":"10.3389\/fmed.2023.1229937","article-title":"Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients","volume":"10","author":"Mori","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025012411212467900_ljae401-B24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025012411212467900_ljae401-B25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2217\/imt-2020-0105","article-title":"Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy","volume":"12","author":"Kartolo","year":"2020","journal-title":"Immunotherapy"},{"key":"2025012411212467900_ljae401-B26","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat Med"},{"key":"2025012411212467900_ljae401-B27","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"2025012411212467900_ljae401-B28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/exd.13321","article-title":"Mutational profiling of acral melanomas in Korean populations","volume":"26","author":"Shim","year":"2017","journal-title":"Exp Dermatol"},{"key":"2025012411212467900_ljae401-B29","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/jnci\/djz005","article-title":"Targeted genomic profiling of acral melanoma","volume":"111","author":"Yeh","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025012411212467900_ljae401-B30","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1101\/gr.213348.116","article-title":"Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma","volume":"27","author":"Liang","year":"2017","journal-title":"Genome Res"},{"key":"2025012411212467900_ljae401-B31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/labinvest.2016.143","article-title":"Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas","volume":"97","author":"Rawson","year":"2017","journal-title":"Lab Invest"},{"key":"2025012411212467900_ljae401-B32","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1158\/1078-0432.CCR-21-3344","article-title":"Integrative genomic profiling uncovers therapeutic targets of acral melanoma in Asian populations","volume":"28","author":"Shi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025012411212467900_ljae401-B33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/CMR.0000000000000688","article-title":"Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas","volume":"30","author":"Holman","year":"2020","journal-title":"Melanoma Res"},{"key":"2025012411212467900_ljae401-B34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2019.07.010","article-title":"Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)","volume":"119","author":"Nathan","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025012411212467900_ljae401-B35","doi-asserted-by":"crossref","first-page":"882471","DOI":"10.3389\/fimmu.2022.882471","article-title":"Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study","volume":"13","author":"Si","year":"2022","journal-title":"Front Immunol"},{"key":"2025012411212467900_ljae401-B36","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaoncol.2023.1363","article-title":"Camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma: the CAP 03 phase 2 nonrandomized clinical trial","volume":"9","author":"Mao","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025012411212467900_ljae401-B37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"2025012411212467900_ljae401-B38","doi-asserted-by":"crossref","first-page":"524700","DOI":"10.3389\/fonc.2020.524700","article-title":"Poor lymphocyte infiltration to primary tumors in acral lentiginous melanoma and mucosal melanoma compared to cutaneous melanoma","volume":"10","author":"Nakamura","year":"2020","journal-title":"Front Oncol"},{"key":"2025012411212467900_ljae401-B39","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-21-3145","article-title":"Single-cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy","volume":"28","author":"Li","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025012411212467900_ljae401-B40","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1038\/s41467-022-34877-3","article-title":"A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"2025012411212467900_ljae401-B41","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","article-title":"Melanoma subtypes demonstrate distinct PD-L1 expression profiles","volume":"97","author":"Kaunitz","year":"2017","journal-title":"Lab Invest"},{"key":"2025012411212467900_ljae401-B42","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/his.13478","article-title":"High density of M2-macrophages in acral lentiginous melanoma compared to superficial spreading melanoma","volume":"72","author":"Zuniga-Castillo","year":"2018","journal-title":"Histopathology"},{"key":"2025012411212467900_ljae401-B43","doi-asserted-by":"crossref","first-page":"e007567","DOI":"10.1136\/jitc-2023-007567","article-title":"Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma","volume":"11","author":"Augustin","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025012411212467900_ljae401-B44","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ccell.2024.04.012","article-title":"Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"2025012411212467900_ljae401-B45","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/CMR.0000000000000476","article-title":"Acral melanoma: a retrospective cohort from the Brazilian National Cancer Institute (INCA)","volume":"28","author":"Nunes","year":"2018","journal-title":"Melanoma Res"},{"key":"2025012411212467900_ljae401-B46","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jid.2017.08.022","article-title":"Distinct patterns of acral melanoma based on site and relative sun exposure","volume":"138","author":"Haugh","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2025012411212467900_ljae401-B47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2015.09.047","article-title":"Other primary systemic cancers in patients with melanoma: Analysis of balanced acral and nonacral melanomas","volume":"74","author":"Bae","year":"2016","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae401\/61013265\/ljae401.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/2\/316\/61013265\/ljae401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/2\/316\/61013265\/ljae401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T11:21:43Z","timestamp":1737717703000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/2\/316\/7831584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,10,23]]},"published-print":{"date-parts":[[2025,1,24]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae401","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,10,23]]}}}